Ian
age 36

Later-onset (Type 3) SMA
treated with SPINRAZA

Biogen Support services for Spinraza patient traveling with friend

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

*Based on commercial patients in the US (including Puerto Rico) through December 2019.

“Around the age of 32, I had moved across the country and started working with a new doctor. I was feeling weaker but learning to accept it. My new doctor mentioned a new treatment to me called SPINRAZA.

“I had never heard of this treatment; to my knowledge, there was no treatment for SMA at that time. I tempered my expectations about what the drug could do for me from the very beginning because I’m a pragmatic dude. I wasn’t going to get excited about something that could potentially not work for me. Still, I was willing to try anything that could potentially slow the progression of my SMA. After doing my own research and talking it over with my parents, I decided to give SPINRAZA a try.

“For my first injection, I took a taxi to the clinic, so I wouldn’t have to drive myself home. My Family Access Manager (FAM), who had helped me arrange things with my insurance, met me there. This was awesome, it was so nice to see a familiar face during my first procedure. The doctor numbed my back before the injection, so all I felt was a slight pressure. I stayed for an hour after the injection and laid down while the doctors ran a few tests. Then I went home and took it easy the rest of the day. Of course, everyone’s experience is different, so it’s important to talk to your doctor about what is right for you.

“I have had six injections so far and have experienced some soreness at the injection site and headaches. Since starting on SPINRAZA, I have maintained the same mobility I have had, and that is a huge victory for me.”

Biogen is compensating Ian for sharing his story. This content has been reviewed for compliance with FDA guidelines. Please keep in mind these are Ian’s experiences with SMA Type 3 and SPINRAZA, and others may have different experiences.

SPINRAZA STORIES

Hear from some of the 1200+ US adults on SPINRAZA.*

View more stories *Based on commercial patients in the US (including Puerto Rico) through December 2019.

Sign up for other SPINRAZA stories

Join today to receive the latest updates from SPINRAZA

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

This information is not intended to replace discussions with your healthcare provider.


INDICATION

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.